Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
Gordon
Leo I
LI
Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA. l-gordon@northwestern.edu
Witzig
Thomas
T
Molina
Arturo
A
Czuczman
Myron
M
Emmanouilides
Christos
C
Joyce
Robin
R
Vo
Katie
K
Theuer
Charles
C
Pohlman
Brad
B
Bartlett
Nancy
N
Wiseman
Greg
G
Darif
Mohamed
M
White
Christine
C
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002461:Cell Line, Transformed; D002986:Clinical Trials as Topic; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008224:Lymphoma, Follicular / Q000473:pathology; D016499:Radioimmunotherapy / Q000379:methods*; D012074:Remission Induction; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D015021:Yttrium Radioisotopes; D000069283:Rituximab; C422802:ibritumomab tiuxetan